CJC-1295 is classified as a Growth Hormone Secretagogue (GHS), also known as DAC:GRF. It is an advanced version of GHRH (1-29), synthetically developed with the intention of producing better pharmacokinetics, potentially increasing Growth Hormone levels and Insulin-Like Growth Factor 1 (IGF-1). According to research, it exhibits the potential to increase the production level of Growth Hormone anywhere from 200-1000%. Moreover, the research developers commented that CJC-1295 may increase “mean plasma IGF-I concentrations by 1.5- to 3-fold.”^[1] This apparent rise in growth hormone level has been reported to persist for about 6-8 days under study conditions. A longer half-life would ensure the increased level of growth hormone production even beyond the initial introduction of the peptide.

Ipamorelin is a growth hormone (GH) secretagogue that has been extensively studied in the diverse biological milieu. It is considered by researchers to be one of the most selective secretagogues and is an apparent agonist of the growth hormone/ghrelin secretagogue receptor.^[1] This potential selectivity is attributed to the fact that Ipamorelin does not appear, in any way, to affect the secretion of other pituitary hormones. These include prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), or Adrenocorticotropic hormone (ACTH). Ipamorelin appears to act via the molecular mimicry of the natural hormone ghrelin, which triggers and stimulates the release of the growth hormone.^[2] This whole process may be regulated by a negative feedback mechanism, which may nullify any ancillary impacts of excess GH production. Researchers suggest that Ipamorelin may impact all physiological processes in which ghrelin is active. Based on their observations, researchers have suggested that Ipamorelin may improve bowel movement and gastric function, enhancing the development and repair of muscles, facilitating the release of insulin hormone from the pancreas, and stimulating the growth of bones. In addition to these potentials, Ipamorelin may also be involved in cellular repair and increased collagen production.^[3] It has also been hypothesized that the peptide may act to improve cognitive function and sleep cycle regulation.

Modified GRF 1-29 (also abbreviated as Mod GRF 1-29), is a synthetic peptide analog of Growth Hormone Releasing Hormone (GHRH). It is a modified version of the first twenty-nine amino acids of the naturally occurring GHRH. This modification has been suggested to provide better stability and potentially reduce metabolic clearance. More specifically, the modifications may involve the substitution of four specific amino acids within the initial 29 amino acids of Growth Hormone-Releasing Hormone (GHRH). These changes occur at the 2nd, 8th, 15th, and 27th positions and may potentially enhance the peptide’s durability against enzymatic degradation, especially by enzymes such as dipeptidyl peptidase-4 (DPP-4). It is hypothesized that replacing L-alanine with D-alanine at the second position may increase resistance to molecular breakdown. Furthermore, replacing asparagine with glutamine at the eighth position might reduce the likelihood of asparagine reconfiguration and amide hydrolysis. Additionally, substituting glycine with alanine at the 15th position may improve bioactivity. Lastly, the switch from methionine to leucine at the 27th position is thought to help prevent methionine oxidation. It may lead to natural growth hormone production and increased levels of IGF-1 (Insulin-Like Growth Factor-1).

CJC-1295 & GHRP-2 blend combines two peptides with different structures; both have been researched for their proposed affinity for receptors in the pituitary gland and other parts of the central nervous system. Despite activating different receptors, CJC-1295 & GHRP-2 may exhibit similar action.

CJC-1295 is a molecule that appears to bind to the growth hormone-releasing hormone (GHRH) receptors, which may cause the release of growth hormone by pituitary cells. CJC-1295 is derived from GHRH 1-29, the shortest functional sequence of GHRH consisting of the first 29 amino acids. CJC-1295 is a tetrasubstituted version of the peptide that is also modified by adding a drug affinity complex (DAC) component called N-epsilon-3-maleimidopropionamide, which appears to bind to plasma proteins and may improve CJC-1295 pharmacokinetics.

GHRP-2, or Growth Hormone Releasing Peptide 2, is a synthetic hexapeptide composed of six amino acids. This peptide appears to bind to ghrelin or growth hormone secretagogue 1a receptors (GHS-R1a) found in the hypothalamus and the pituitary gland. As a result, GHRP-2 also appears to stimulate the production of growth hormone (GH) in pituitary cells that express this receptor.

Modified Growth Hormone Releasing Factor (Mod GRF 1-29) and Growth Hormone Releasing Peptide-6 (GHRP-6) are two peptides that researchers believe may support the secretion of growth hormone (GH) from cells in the anterior pituitary gland. The peptides may offer this support through distinct biological pathways. Mod GRF (1-29) is a synthetic peptide derived from Growth Hormone Releasing Hormone (GHRH), an endogenous hormone consisting of 44 amino acids that stimulates GH release. Some studies have indicated that the initial 29 amino acids of GHRH retain their full biological activity.^[1] Modifications to this fragment, resulting in Mod GRF (1-29), are believed to increase its potency and prolong its duration of action, possibly due to better-supported stability against enzymatic degradation.

Studies have suggested that a maximal output of endogenous growth hormone (GH) from the anterior pituitary gland might be attained through a combination of growth hormone-releasing hormone (GHRH) analog and agonist of growth hormone secretagogue receptor (GHSR).^[1] The combination of Ipamorelin with Modified GRF is one of the various combinations researchers have studied in an effort to achieve maximal growth hormone production. Interestingly, more specific results appear to be achieved beyond the increase in GH synthesis by refining the choice of GHRH and GHSR evaluated in a particular study. Modified GRF, which researchers have suggested may be a potent GHRH analog, may have impacts beyond growth hormone release. It has been speculated to impact intestinal inflammation, tissue repair, and cardiac function in addition to researchers’ suppositions on its impact on growth hormone release. Ipamorelin, classified as a growth hormone secretagogue, appears to interact with the GHSRs, also known as ghrelin receptors, and may have the potential to impact bone growth. Activating the ghrelin receptors may affect appetite, to increase food consumption and total weight gain. Depending on the desired outcome of the particular study, namely the addition or reduction of weight, this specific receptor activity may be mitigated by adding lipolytic molecules, which may help minimize the possibility of fat increase. Fragment 176-191 is often combined with Ipamorelin and other research peptides. The peptide known as Fragment 176-191, also referred to as hGH Fragment 176-191, Frag 176-191, tyr-hGH 177-191, or AOD-9604, is hypothesized to specifically target the fat-reduction pathways of growth hormone. This peptide consists of a sequence of 16 amino acids derived from the terminal portion of the growth hormone molecule, identified by researchers as the “lipolytic fragment” due to its potential fat-burning capabilities. The term ‘lipolytic’ describes the fragment’s capacity to promote fat breakdown. To enhance the peptide’s stability, the initial amino acid in the hGH Fragment 176-191 sequence is substituted with tyrosine, leading to its alternate designation as Fragment tyr-hGH 177-191.

Fragment 176-191 houses the primary proposed ‘lipolytic fragment’ of the growth hormone (hGH) and it potentially targets the beta-3 adrenergic receptors (ADRB3), which may facilitate its suggested weight-loss potential. This peptide is proposed to amplify fat burning in adipose tissue cells and stimulate ‘thermogenesis’ in skeletal muscle cells via these receptors.^[1]

CJC-1295 (Mod GRF 1-29), is an apparently enhanced version of GHRH (1-29) crafted to potentially optimize its pharmacokinetics. It is posited to elevate growth hormone and Insulin-Like Growth Factor 1 (IGF-1) levels. Research suggests it may increase growth hormone production between 200-1000%. Furthermore, CJC-1295 is believed to increase plasma IGF-I concentrations by 1.5- to 3-fold.^[2]

Ipamorelin, a five-amino-acid chain, is identified as a Growth Hormone Secretagogue (GHS). It is posited to function similarly to Growth Hormone Releasing Peptides (GHRPs) and to apparently emulate the natural hunger hormone, ghrelin, particularly its potential to stimulate the release of hGH from pituitary cells.^[3] A notable feature of Ipamorelin research is its apparent selectivity and its reported negligible influence on the secretion of other pituitary hormones like cortisol, prolactin, and aldosterone.